Florida alleges two rival pharmacy-benefit managers used a services agreement to align reimbursement rates downward, cutting some pharmacy payments by as much as 80%.
A cell-by-cell map of the striatum found 31 neuronal subpopulations, nine of them new — and showed why Huntington’s destroys some cells first, and why mouse models may mislead on addiction.
Triglycerides down about 80%, acute pancreatitis events down 78% — and eliminated entirely in the highest-risk patients. Plozasiran silences the gene for the protein that blocks fat clearance.
Essential thrombocythemia has been managed with drugs approved before most of its current patients were diagnosed. Besremi is the first new option in nearly three decades — and it beat the incumbent head to head.
If long Covid is driven by virus that never fully cleared, a longer antiviral course should help. A three-arm randomised trial tested that directly and found nothing.
BTK inhibitors were supposed to be the next step in multiple sclerosis. Liver toxicity kept derailing them. Novartis reports superiority over a standard oral drug without that signal.
Envudeucitinib missed every endpoint at every dose across 408 patients. Alumis is pointing to a subgroup — which is what companies do when the primary analysis leaves nothing else to point at.
Surgeons spend operations looking away from the patient at wall-mounted screens. Stryker has the first FDA authorisation to put those images inside a headset instead.
CPAP works when people use it, and enormous numbers do not. AD109 is the first drug aimed at the mechanical cause of sleep apnea rather than at its consequences.
Immune memory is supposed to belong to T and B cells. A lung cell that is neither turns out to sustain the local defences that stop flu at the airway — and adding its protein to a nasal vaccine worked.
The last migraine prevention guidelines predate every drug designed for migraine. The update finally ranks the CGRP therapies — and quietly demonstrates how guideline ratings can penalise cheap generics.
Block one enzyme and triple-negative breast cancer cells escape onto a backup pathway. Block the backup too and they die by ferroptosis — and one half of the combination is already an approved drug.